Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 6/20 | 0.34 |
| ▸ | PPARD | Q03181 | 6/20 | 0.34 |
| ▸ | PPARA | Q07869 | 6/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.34 |
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TLR2 | O60603 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | FABP4 | P15090 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.34 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14322814 | 0.84 | PTGS1 (0.33) | KMT2ASMN1; SMN2FAAHMGLLMEN1 | |
| SCHEMBL1943663 | 0.83 | TSHR (0.40) | SCDKMT2APPARGPPARDPPARA | |
| SCHEMBL7762150 | 0.82 | KMT2A (0.36) | KMT2ASMN1; SMN2CES2FAAHMGLL | |
| Hydrochloric Acid SCHEMBL7762499 | 0.81 | KMT2A (0.35) | SCDKMT2ASMN1; SMN2CES2FAAH | |
| SCHEMBL5066051 | 0.80 | MGLL (0.44) | KMT2ACES2FAAHMGLLPPARG | |
| SCHEMBL31307518 | 0.80 | KMT2A (0.34) | SCDKMT2ASMN1; SMN2CES2FAAH | |
| SCHEMBL826506 | 0.80 | KMT2A (0.37) | SCDKMT2ASMN1; SMN2CES2FAAH | |
| SCHEMBL4302803 | 0.80 | KMT2A (0.37) | SCDKMT2ASMN1; SMN2CES2FAAH | |
| SCHEMBL825652 | 0.80 | KMT2A (0.37) | SCDKMT2ASMN1; SMN2CES2FAAH | |
| SCHEMBL18705335 | 0.79 | CYP1A2 (0.35) | SCDKMT2ASMN1; SMN2HDAC11TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408470-A1 | Soluble non-depot insulin conjugates and uses thereof | Smartcells, Inc. (US) | 2012-01-25 | — | — | EP | claimed |
| WO-2010107520-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-09-23 | — | — | WO | claimed |
| US-20140037699-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8569231-B2 | Soluble non-depot insulin conjugates and uses thereof | SMARTCELLS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2408470-A1 | Soluble non-depot insulin conjugates and uses thereof | Smartcells, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20120010134-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | SMARTCELLS, INC. | 2012-01-12 | — | — | US | disclosed |
| WO-2010107520-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| US-7179446-B2 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-7090828-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-08-15 | — | — | US | disclosed |
| US-7052673-B2 | Pharmaceuticals for the imaging of angiogenic disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060003926-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | LANTHEUS MEDICAL IMAGING, INC. | 2006-01-05 | — | — | US | disclosed |
| US-20020106325-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | CARPENTER ALAN P (US) | 2002-08-08 | — | — | US | disclosed |
| WO-2002055111-A2 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | BRISTOL MYERS SQUIBB MEDICAL I (US) | 2002-07-18 | — | — | WO | disclosed |
| US-20020001566-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-03 | — | — | US | disclosed |
| WO-2001097861-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001097860-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS FOR USE IN COMBINATION THERAPY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| EP-1140864-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1068224-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | Du Pont Pharmaceuticals Company (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-2000035887-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARM CO (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-1999058162-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140037699-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | GPR119, IAPP, IRS1 | SCD 1114/4885KMT2A 1976/4885SMN1; SMN2 2666/4885 |
| US-20120010134-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | GPR119, IAPP, IRS1 | SCD 1114/4885KMT2A 1976/4885SMN1; SMN2 2666/4885 |
| US-20020106325-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | TNNI3, ASGR1, TNNT2 | SCD 4406/4885KMT2A 4775/4885SMN1; SMN2 3100/4885 |
| US-20020001566-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | VEGFA, FLT4, FLT1 | SCD 4469/4885KMT2A 4507/4885SMN1; SMN2 4339/4885 |
| US-20060003926-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | FLT4, VEGFA, FLT1 | SCD 3763/4885KMT2A 4679/4885SMN1; SMN2 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.